Loading clinical trials...
Loading clinical trials...
Hemorrhoidal disease is a common cause of gastroenterology visits. In the United States, it is considered the 3rd most common gastrointestinal diagnosis with nearly 4 million scheduled or emergency visits. In France, self-reported questionnaires estimate that one person in five has suffered at least one hemorrhoidal attack in the past year.
Hemorrhoidal disease significantly alters the quality of life, can be life threatening in case of heavy bleeding and has a significant economic impact. However, there are still many unknowns regarding the different types of hemorrhoidal disease, its symptoms, its natural history, its etiology, its triggering and promoting factors, the associated pathologies, the therapeutic indications, etc. In addition, the therapeutic management is not consensual, especially since the therapeutic arsenal is constantly expanding over the last 20 years with the advent of minimally invasive surgical techniques. The aim of the work is to answer some of these questions on the basis of a prospective cohort of patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Groupe Hospitalier Paris Saint Joseph
Paris, Île-de-France Region, France
Start Date
June 15, 2020
Primary Completion Date
June 15, 2021
Completion Date
March 6, 2023
Last Updated
March 7, 2023
500
ACTUAL participants
Lead Sponsor
Fondation Hôpital Saint-Joseph
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06660680